FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2151492933> ?p ?o ?g. }

• W2151492933 endingPage "1693" @default.
• W2151492933 startingPage "1690" @default.
• W2151492933 abstract "A biochemical decrease in circulating testosterone (total testosterone, TT ≤ 10.4 nMol/L or 300 ng/dL) is a relatively common condition, particularly in aging men. Data derived from a Florentine sub‐analysis of the European Male Aging Study indicate that, in this geographic area, 8% of the general population, aged 40 years or older, have the condition, although asymptomatic [1]. However, all the guideline recommendations of dedicated scientific societies suggest that the diagnosis of late‐onset hypogonadism (LOH) must be considered only in the presence of specific symptoms. It is well recognized that sexual dysfunctions are the most specific symptoms characterizing male hypogonadism (HG) during adulthood [2]. In a large series of subjects consulting an andrology unit for sexual dysfunction in Florence, overt HG was present in 20% of the entire cohort [1]. Hence, having sexual dysfunction appears to double the chance of having low testosterone (T). Currently, the question is whether it is safe for the sexual medicine clinician to prescribe T preparations for subjects with low T and specific symptoms. The answer is not easy, in particular considering recent claims on safety and on the reported increased risk of cardiovascular (CV) events associated with T use [3]. The Coordination Group for Mutual Recognition and Decentralised Procedures‐Human (CMDh), a regulatory body representing European Member States—after a review by the European Medicines Association (EMA)'s Pharmacovigilance Risk Assessment Committee (PRAC)—has agreed by consensus that there is no consistent evidence of an increased risk of heart problems with T medicines in HG men (http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/Testosterone‐containing_medicines/human_referral_prac_000037.jsp&mid=WC0b01ac05805c516f). PRAC also noted that the lack of T itself could increase the risk of heart problems. However, the use of T in healthy older men is not an authorized use in the European Union (EU, http://www.ema.europa.eu). A few months after the EMA's PRAC position statement, the cognate U.S. agency, the Food and Drug Administration (FDA), released an opposite opinion for a possible elevated CV risk associated with starting or continuing T therapy (http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm). The FDA cautions that prescribing T products is approved only for men who have low T levels caused by certain medical conditions. In particular, only subjects with primary or secondary HG (sHG) resulting from problems within the testis, pituitary, or hypothalamus (e.g. genetic problems, or damage from surgery, chemotherapy, or infection) should be treated. In contrast, the FDA emphasized that the benefits and safety of T medications have not been established for the treatment of low T levels due to aging, even if a man's symptoms seem related to low T. In other words, only hypogonadal men with a well‐defined etiological condition must be systematically treated, but not those with an age‐related T decrease. Table 1 shows the main causes of HG (i.e. ≤10.4 nMol/L or 300 ng/dL) in a large series of men consulting for sexual dysfunction in Florence (n = 4220), categorized according to LH levels [4]. Only in one half of the cases of primary HG can an etiological condition be identified. Klinefelter syndrome accounts for the majority of testicular disorders. The figure is even more impressive when sHG is considered. In this case, a causal condition can be inferred only in 10% of the subjects. This is particularly interesting, because, as stated before, sHG is by far the most prevalent form of LOH. Therefore, according to FDA criteria, more than 85% of the symptomatic subjects with low T consulting for sexual dysfunction should not be treated, because the T decline is “age‐related” and therefore treatment would put patients at risk for cardiac or other major adverse CV events (MACE). Is this indication evidence based? We recently published a meta‐analysis restricted to T placebo‐controlled randomized controlled trials (RCTs) on different primary outcomes because studies with T and specific CV endpoints as the primary outcome were few and of short duration [6]. Our systematic review did not substantiate the view that T treatment brings with it any additional risk of CV‐related adverse events, when HG is properly diagnosed and replacement therapy correctly performed. When a separate analysis was performed according to the baseline population characteristics, similar results were obtained even in studies enrolling subjects with an age‐related condition [6]. Recently, results from the TSAT study have been reported [7]. This is a multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group, 16‐week trial on T supplementation in 596 adult, hypogonadal men with decreased energy or decreased sexual drive [7]. By combining the results from this study with those from the aforementioned meta‐analysis on RCTs performed after excluding those trials enrolling subjects with a well‐known cause of HG [6], we now show (Figure 1 ) that the use of T is not associated with any significant difference in the incidence of MACE (MH‐OR: 0.89 [0.50–1.61]; P = 0.70) suggesting, in aging men, a neutral effect of T substitution on MACE outcomes. Similar results were obtained when any CV‐related events were considered (not shown)." @default.
• W2151492933 created "2016-06-24" @default.
• W2151492933 creator A5049759930 @default.
• W2151492933 creator A5056340385 @default.
• W2151492933 date "2015-08-01" @default.
• W2151492933 modified "2023-09-27" @default.
• W2151492933 title "Perspective: Regulatory Agencies' Changes to Testosterone Product Labeling" @default.
• W2151492933 cites W1549971355 @default.
• W2151492933 cites W1894043417 @default.
• W2151492933 cites W1983334491 @default.
• W2151492933 cites W2030189949 @default.
• W2151492933 cites W2058308329 @default.
• W2151492933 cites W2096237552 @default.
• W2151492933 cites W2102933102 @default.
• W2151492933 cites W2110425298 @default.
• W2151492933 cites W2119148112 @default.
• W2151492933 doi "https://doi.org/10.1111/jsm.12951" @default.
• W2151492933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26289540" @default.
• W2151492933 hasPublicationYear "2015" @default.
• W2151492933 type Work @default.
• W2151492933 sameAs 2151492933 @default.
• W2151492933 citedByCount "24" @default.
• W2151492933 countsByYear W21514929332015 @default.
• W2151492933 countsByYear W21514929332016 @default.
• W2151492933 countsByYear W21514929332017 @default.
• W2151492933 countsByYear W21514929332018 @default.
• W2151492933 countsByYear W21514929332019 @default.
• W2151492933 countsByYear W21514929332020 @default.
• W2151492933 countsByYear W21514929332021 @default.
• W2151492933 countsByYear W21514929332022 @default.
• W2151492933 countsByYear W21514929332023 @default.
• W2151492933 crossrefType "journal-article" @default.
• W2151492933 hasAuthorship W2151492933A5049759930 @default.
• W2151492933 hasAuthorship W2151492933A5056340385 @default.
• W2151492933 hasConcept C126322002 @default.
• W2151492933 hasConcept C142724271 @default.
• W2151492933 hasConcept C2777910003 @default.
• W2151492933 hasConcept C2778093883 @default.
• W2151492933 hasConcept C2779279991 @default.
• W2151492933 hasConcept C2779929075 @default.
• W2151492933 hasConcept C2780182762 @default.
• W2151492933 hasConcept C2908647359 @default.
• W2151492933 hasConcept C29456083 @default.
• W2151492933 hasConcept C71924100 @default.
• W2151492933 hasConcept C72563966 @default.
• W2151492933 hasConcept C99454951 @default.
• W2151492933 hasConceptScore W2151492933C126322002 @default.
• W2151492933 hasConceptScore W2151492933C142724271 @default.
• W2151492933 hasConceptScore W2151492933C2777910003 @default.
• W2151492933 hasConceptScore W2151492933C2778093883 @default.
• W2151492933 hasConceptScore W2151492933C2779279991 @default.
• W2151492933 hasConceptScore W2151492933C2779929075 @default.
• W2151492933 hasConceptScore W2151492933C2780182762 @default.
• W2151492933 hasConceptScore W2151492933C2908647359 @default.
• W2151492933 hasConceptScore W2151492933C29456083 @default.
• W2151492933 hasConceptScore W2151492933C71924100 @default.
• W2151492933 hasConceptScore W2151492933C72563966 @default.
• W2151492933 hasConceptScore W2151492933C99454951 @default.
• W2151492933 hasIssue "8" @default.
• W2151492933 hasLocation W21514929331 @default.
• W2151492933 hasLocation W21514929332 @default.
• W2151492933 hasOpenAccess W2151492933 @default.
• W2151492933 hasPrimaryLocation W21514929331 @default.
• W2151492933 hasRelatedWork W1984473184 @default.
• W2151492933 hasRelatedWork W2066097372 @default.
• W2151492933 hasRelatedWork W2076940792 @default.
• W2151492933 hasRelatedWork W2100733818 @default.
• W2151492933 hasRelatedWork W2166421022 @default.
• W2151492933 hasRelatedWork W2178482406 @default.
• W2151492933 hasRelatedWork W2296044489 @default.
• W2151492933 hasRelatedWork W2390555057 @default.
• W2151492933 hasRelatedWork W2508370915 @default.
• W2151492933 hasRelatedWork W2804257877 @default.
• W2151492933 hasVolume "12" @default.
• W2151492933 isParatext "false" @default.
• W2151492933 isRetracted "false" @default.
• W2151492933 magId "2151492933" @default.
• W2151492933 workType "article" @default.